<qa>  What is Selumetinib given twice daily on 5 out of 7 days in childrenPhase I and II study of the MEK inhibitor Selumetinib given twice daily on 5 out of 7 days in children with NF1 and inoperable plexiform neurofibromas or progressiverelapsed optic pathway gliomas. 